Good Morning Extra,Yes you are correct & for sure we don’t know...

Good Morning Extra,

Yes you are correct & for sure we don’t know when the licensing deals will hit. I’m sure that DXB have a good idea of what is an acceptable offer, and beneficial to us if there are multiple offers for each jurisdiction, which from the language it appears to be the case. So there could even be a bit of a bidding war going on behind the scenes.

Something that I have been thinking about is potentially a big pharma taking USA, South America and China/Asia. From reading a lot of pharma news, it’s not like BP don’t have a presence in these countries/territories. Nina has said they are looking for companies that have the capabilities to commercialise & market the drug (my words, paraphrased, that’s the gist though).

It could end up being more beneficial to a BP to take a big chunk, rather than bits, if they are going to outlay cash for commercialisation & marketing. Drug Advertising for prescription medication is a bit different overseas than what is allowed here in Australia.

@singhgu works in the Pharma industry, he has told us that, so be interesting to hear your thoughts on this.

We don’t need a quickie deal now, the remainder of the trial is fully funded, and yes also R&D rebates as you mentioned. I think something else that maybe overlooked which I mentioned again yesterday, is the development of DMX-200 for other kidney diseases. Also pulmonary fibrosis. I believe Advanz has first dibs on that in their jurisdictions. For DKD for example though, BP would be ideal to run a global Ph3 trial if they were to accept a licensing deal in multiple indications. The trial DXB are running at present is a single Ph3 in rare disease. We think this is expensive, try a common disease like DKD & it will be 2 x dual Ph3 with thousands of patients! So have a think about these logistical & financial hurdles & why further development is on the backburner. The assets exist, but there are big $$$ for Pharma companies in rare diseases & tax/other benefits attached.

To develop the drug in other indications, they would literally be reaping in revenue whilst that is occurring in the exclusivity period for FSGS. We have patients on trials & SGLT2i are allowed. There have been no issues combining ARB + SGLT2is + DMX-200.

Anyway, just some of my personal thoughts & all that information has come from DXB over the years in regards to combination therapy.

Have a good day folks.